0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Childhood Maltreatment, Altered Limbic Neurobiology, and Substance Use Relapse Severity via Trauma-Specific Reductions in Limbic Gray Matter Volume ONLINE FIRST

Nicholas T. Van Dam, PhD1; Kenneth Rando, BS2; Marc N. Potenza, PhD, MD2; Keri Tuit, PsyD2; Rajita Sinha, PhD2
[+] Author Affiliations
1Department of Psychiatry, New York University School of Medicine, New York
2Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
JAMA Psychiatry. Published online June 11, 2014. doi:10.1001/jamapsychiatry.2014.680
Text Size: A A A
Published online

Importance  Substance use disorders (SUDs) are among the most common sequelae of childhood maltreatment, yet the independent contributions of SUDs and childhood maltreatment to neurobiological changes and the effect of the latter on relapse risk (a critical variable in addiction treatment) are relatively unknown.

Objectives  To identify structural neural characteristics independently associated with childhood maltreatment (CM; a common type of childhood adversity), comparing a sample with SUD with a demographically comparable control sample, and to examine the relationship between CM-related structural brain changes and subsequent relapse.

Design, Setting, and Participants  Structural magnetic resonance imaging study comparing 79 treatment-engaged participants with SUD in acute remission in inpatient treatment at a community mental health center vs 98 healthy control participants at an outpatient research center at an academic medical center. Both groups included individuals with a range of CM experiences. Participants with SUD were followed up prospectively for 90 days to assess relapse and relapse severity.

Intervention  Standard 12-step, recovery-based, inpatient addiction treatment for all participants with SUD.

Main Outcomes and Measures  Gray matter volume (GMV), subsequent substance use relapse, days to relapse, and severity of relapse.

Results  Controlling for SUD and psychiatric comorbidity, CM (dichotomously classified) was uniquely associated with lower GMV across all participants in the left hippocampus (cornu ammonis 1-3, dentate gyrus), parahippocampus (presubiculum, parasubiculum, prosubiculum, subiculum, and entorhinal cortex), and anterior fusiform gyrus (corrected P < .05; uncorrected P = .001). Among the sample with SUD, CM prospectively predicted a shorter relapse to use of any drug (P = .048), while CM-related GMV reductions predicted severity of substance use relapse (P = .04).

Conclusions and Relevance  Findings indicate that CM was related to decreased GMV in limbic regions, which in turn predicted increased risk of relapse in SUD. These results suggest that CM may significantly affect the course of SUD treatment outcomes and that SUD treatment planning may benefit from identifying and addressing CM.

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Place holder to copy figure label and caption
Figure 1.
Gray Matter Volume Differences Related to Childhood Maltreatment

Using whole-brain voxel-based morphometry, childhood maltreatment was associated with lower mean gray matter volume, after controlling for substance use disorder, psychiatric history, age, sex, total intracranial volume, and substance dependence by age, in the left medial temporal lobe (1087 voxels; maximum: x = −20, y = −16, z = −26). A, The gray matter volume cluster predominantly includes regions of the hippocampus and parahippocampal and fusiform gyri. Statistical parametric maps have been height thresholded at P < .005 (t ≥ 2.61) and cluster thresholded using topological false discovery rate to set the overall error rate to P < .05. B, Box-and-whisker plot of estimated, standardized region-of-interest (ROI) cluster volumes by group (no trauma vs trauma). The shaded boxes indicate the 75th (top) and 25th (bottom) percentiles; horizontal lines in the middle of the boxes, the median (50th percentile); and whiskers, the minimum and maximum volumes.aA t test revealed significant differences in the estimated volumes for the ROI between the 2 groups at P < .001.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Gray Matter Volume Differences Related to Substance Use Disorders

Using whole-brain voxel-based morphometry, substance use disorder was associated with lower mean gray matter volume, after controlling for childhood maltreatment, psychiatric history, age, sex, total intracranial volume, and substance use disorders by age, across 4 clusters. Gray matter volume differences are depicted as statistical parametric maps on rendered surfaces in the bilateral thalamus (1337 voxels; maximum: x = 6, y = −4, z = 10), left midcingulate gyrus and bilateral supplementary motor area (3899 voxels; maximum: x = −6, y = −31, z = 48), bilateral posterior cingulate gyrus and right cuneus and precuneus (2166 voxels; maximum: x = −5, y = −61, z = 7), and right fusiform gyrus (1157 voxels; maximum: x = 35, y = −73, z = −15). Statistical parametric maps have been height thresholded at P < .005 (t ≥ 2.61) and cluster thresholded using topological false discovery rate to set the overall error rate to P < .05.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.
Relapse Rate and Severity by Trauma Group and Childhood Maltreatment–Related Gray Matter Volume Differences

Among the subset of the substance-dependent sample for whom additional data were available (n = 72 [91.1%]), relapse time course was examined as a function of childhood maltreatment (A), and severity of relapse (defined as maximum number of days of drug use [alcohol, cocaine, and cannabis] during the 90-day follow-up) was examined as a function of childhood maltreatment–predicted gray matter volume differences in a whole-brain identified region of interest (ROI) (B and C). A, Significantly faster rate of drug relapse for participants with childhood maltreatment compared with those without childhood maltreatment (P value reflects the generalized Wilcoxon χ2 test). B, Correlation between ROI gray matter volume and severity of relapse in the entire subsample (n = 72). C, Relationship between ROI gray matter volume and severity of relapse among those individuals for whom severity of relapse was greater than 0 days (n = 52 [72.2% of subsample]).

Graphic Jump Location

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Related Multimedia

Author Interview

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();